GlaxoSmithKline PLC Stock Options

GSK Stock  USD 42.87  0.12  0.28%   
GlaxoSmithKline PLC's option chain provides insight into all available option contracts written on GlaxoSmithKline PLC's stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of GlaxoSmithKline PLC's stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given GlaxoSmithKline option contract.

In The Money vs. Out of Money Option Contracts on GlaxoSmithKline PLC

Analyzing GlaxoSmithKline PLC's in-the-money options over time can help investors to take a profitable long position in GlaxoSmithKline PLC regardless of its overall volatility. This is especially true when GlaxoSmithKline PLC's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money GlaxoSmithKline PLC's options could be used as guardians of the underlying stock as they move almost dollar for dollar with GlaxoSmithKline PLC's stock while costing only a fraction of its price.
GlaxoSmithKline PLC's latest option contracts expiring on 2024-04-05 are carrying combined implied volatility of 18.85 with a put-to-call open interest ratio of 0.08 over 66 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2024-04-05. The current put volume is at 2, with calls trading at the volume of 359. This yields a 0.01 put-to-call volume ratio. The GlaxoSmithKline PLC option chain provides detailed quote and price information for the current GlaxoSmithKline PLC ADR option contracts. It shows all of GlaxoSmithKline PLC's listed puts, calls, expiration dates, strike prices, and other pricing information.

Open Interest Against 2024-04-05 Option Contracts

GlaxoSmithKline PLC option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in GlaxoSmithKline PLC's lending market. For example, when GlaxoSmithKline PLC's puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on GlaxoSmithKline PLC, he or she must hedge the risk by shorting GlaxoSmithKline PLC stock over its option's life.
The chart above shows GlaxoSmithKline PLC's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. GlaxoSmithKline PLC's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for GlaxoSmithKline PLC's option, there is no secondary market available for investors to trade.

GlaxoSmithKline PLC Maximum Pain Price across 2024-04-05 Option Contracts

Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as GlaxoSmithKline PLC close to expiration to expire worthless. According to most research, approximately 10% to 15% of all stock options are exercised, while about 35% expire worthlessly, with roughly 50% traded out before the expiration date. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
GlaxoSmithKline PLC's stock options are financial instruments that give investors the right to buy or sell shares of GlaxoSmithKline PLC ADR common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell GlaxoSmithKline stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If GlaxoSmithKline PLC's stock price goes up or down, the stock options follow.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Please note that buying 'in-the-money' options on GlaxoSmithKline PLC lessens the impact of time decay, as they carry both intrinsic and time value. So, even if GlaxoSmithKline PLC's value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money GlaxoSmithKline PLC contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if GlaxoSmithKline Stock moves the wrong way.
At this time, GlaxoSmithKline PLC's Total Stockholder Equity is quite stable compared to the past year. Common Stock Total Equity is expected to rise to about 1.6 B this year, although the value of Common Stock will most likely fall to about 1.3 B.

GlaxoSmithKline PLC ADR In The Money Call Balance

When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying GlaxoSmithKline PLC's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on GlaxoSmithKline PLC ADR are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

GlaxoSmithKline Current Options Market Mood

GlaxoSmithKline PLC's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps GlaxoSmithKline Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of GlaxoSmithKline PLC's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. GlaxoSmithKline PLC's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current GlaxoSmithKline PLC's option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.

Rule 16 of the current GlaxoSmithKline contract

Base on the Rule 16, the options market is currently suggesting that GlaxoSmithKline PLC ADR will have an average daily up or down price movement of about 1.18% per day over the life of the 2024-04-05 option contract. With GlaxoSmithKline PLC trading at USD 42.87, that is roughly USD 0.51. If you think that the market is fully incorporating GlaxoSmithKline PLC's daily price movement you should consider buying GlaxoSmithKline PLC ADR options at the current volatility level of 18.85%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Purchasing GlaxoSmithKline PLC options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" GlaxoSmithKline calls. Remember, the seller must deliver GlaxoSmithKline PLC ADR stock to the call owner when a call is exercised.

GlaxoSmithKline PLC Option Chain

When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
GlaxoSmithKline PLC's option chain is a display of a range of information that helps investors for ways to trade options on GlaxoSmithKline. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for GlaxoSmithKline. It also shows strike prices and maturity days for a GlaxoSmithKline PLC against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
DeltaGammaOpen IntExpirationCurrent SpreadLast Price
Call
2024-04-05 CALL at $25.00.93870.00702024-04-0517.0 - 19.80.0In
Call
2024-04-05 CALL at $28.00.91560.010102024-04-0514.3 - 16.80.0In
Call
2024-04-05 CALL at $29.00.95290.00902024-04-0513.0 - 15.20.0In
Call
2024-04-05 CALL at $30.00.91650.012402024-04-0512.0 - 14.80.0In
Call
2024-04-05 CALL at $31.00.89380.014502024-04-0511.1 - 14.10.0In
Call
2024-04-05 CALL at $32.00.88620.016402024-04-0510.1 - 13.10.0In
Call
2024-04-05 CALL at $33.00.86970.018702024-04-059.3 - 12.10.0In
Call
2024-04-05 CALL at $34.00.87280.021502024-04-058.0 - 11.10.0In
Call
2024-04-05 CALL at $35.00.87270.024902024-04-057.0 - 9.90.0In
Call
2024-04-05 CALL at $36.00.84420.029202024-04-056.1 - 9.10.0In
Call
2024-04-05 CALL at $36.50.84790.032202024-04-055.7 - 8.30.0In
Call
2024-04-05 CALL at $37.00.83430.034902024-04-055.0 - 8.10.0In
Call
2024-04-05 CALL at $37.50.82560.038402024-04-054.5 - 7.60.0In
Call
2024-04-05 CALL at $38.00.86140.043802024-04-053.4 - 7.10.0In
Call
2024-04-05 CALL at $38.50.81130.047702024-04-053.4 - 6.60.0In
Call
2024-04-05 CALL at $39.00.85260.0566242024-04-053.1 - 4.74.2In
Call
2024-04-05 CALL at $39.50.80010.062802024-04-052.5 - 5.30.0In
Call
2024-04-05 CALL at $40.00.78380.0725342024-04-052.0 - 4.82.65In
Call
2024-04-05 CALL at $41.00.88420.119602024-04-051.65 - 2.32.02In
Call
2024-04-05 CALL at $42.00.74860.2337742024-04-050.95 - 1.651.09In
Call
2024-04-05 CALL at $43.00.46130.372339322024-04-050.3 - 0.450.37Out
Call
2024-04-05 CALL at $44.00.1680.22221122024-04-050.05 - 0.150.1Out
Call
2024-04-05 CALL at $45.00.06740.0954122024-04-050.0 - 0.10.04Out
 Put
2024-04-05 PUT at $42.0-0.17320.26741212024-04-050.05 - 0.250.09Out
 Put
2024-04-05 PUT at $43.0-0.55030.45562112024-04-050.4 - 0.50.41In
 Put
2024-04-05 PUT at $44.0-0.80840.219202024-04-051.1 - 1.40.0In
 Put
2024-04-05 PUT at $45.0-0.83330.1202024-04-051.7 - 2.30.0In
 Put
2024-04-05 PUT at $46.0-0.76640.078702024-04-052.15 - 5.10.0In
 Put
2024-04-05 PUT at $47.0-0.79670.063502024-04-053.2 - 6.00.0In
 Put
2024-04-05 PUT at $48.0-0.77180.050902024-04-054.7 - 7.00.0In
 Put
2024-04-05 PUT at $49.0-0.82910.045102024-04-055.3 - 7.90.0In
 Put
2024-04-05 PUT at $50.0-0.84040.039402024-04-056.3 - 8.90.0In
 Put
2024-04-05 PUT at $51.0-0.85890.034702024-04-057.2 - 9.90.0In
 Put
2024-04-05 PUT at $52.0-0.86630.031102024-04-058.3 - 10.80.0In
 Put
2024-04-05 PUT at $53.0-0.87270.028102024-04-059.2 - 11.90.0In
 Put
2024-04-05 PUT at $54.0-0.88710.025202024-04-0510.1 - 12.90.0In
 Put
2024-04-05 PUT at $55.0-0.88290.023702024-04-0511.2 - 13.90.0In

GlaxoSmithKline PLC Total Stockholder Equity Over Time

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.
   Total Stockholder Equity   
       Timeline  

GlaxoSmithKline Total Stockholder Equity

Total Stockholder Equity

14.01 Billion

At this time, GlaxoSmithKline PLC's Total Stockholder Equity is quite stable compared to the past year.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
3.03
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.